Cristal Health (established in May 2019) has been developed as a sustainable way to accelerate the UK-CRIS programme. The UK-CRIS network operates a managed service for secure access to one of the world's largest repositories of de-identified patient data relating to mental health and dementia conditions.
Cristal Health presents a real opportunity for accelerating and translating new discovery medicine, including prevention and treatment, into better health outcomes for sufferers of mental illness and their families. - Mike Dennis, CEO, Cristal Health
Mike Denis, CEO, Cristal Health, said,
"I'm honoured to be leading the team in the joint partnership between the NHS and academia working with industry using real world health data. We're able to add value by continually enriching the clinical content available to clinicians, researchers and scientists which will truly deliver many more opportunities to predict, identify, prevent or manage mental health conditions in the UK."
The market for real world evidence and data is projected to grow as organisations seek to reduce costs and time,
The spinning out of remarkable new companies like Cristal Health is great news. It brings in investment which allows for exciting initiatives and innovative activity developed in the NHS and Universities to grow more quickly and become sustainable. Everyone benefits and most importantly our patients. - Professor John Geddes, Head of Department of Psychiatry
Cristal Health will focus on three areas:
• Developing offerings to help in early stage drug discovery, reduce clinical trial costs by 12-30%, support post launch and Phase IV evaluation (i.e. following approval) and pharmacovigilance (safety monitoring).
• Supporting NHS Trusts in generating revenue from increased participation in the global trials market and developing tools that support service reviews through ongoing monitoring
• Supporting academic research by developing tools to support text-mining to create real knowledge from distributed and heterogeneous data
Cristal Health will use any profits generated to re-invest into its core purpose of accelerating improvements in medical research, services and outcomes for patients with a mental illness and/or dementia.